Thus, targeting the mechanism preserving the mitochondrial redox balance and thereby inhibiting NLRP3 inflammasome activation in CKD patients with hyperlipidemia may be an attractive therapeutic approach. The gene discussed is NLRP3; the disease is hyperlipidemia.